EF Hutton initiated coverage of OS Therapies with a Buy rating and $21 price target. OS uses a modified listeria bacteria to target HERII-expressing cancer cells, the analyst tells investors in a research note. The firm views the initial indication of ultra-orphan osteosarcoma as a “leapfrog strategy” for changing how HERII cancers are treated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX: